N/A N=179 Intervention to Reduce Dietary Sodium in Hemodialysis
Renal Dialysis
Primary: Time Specific Interdialytic Weight Gain (Baseline) — 1.2; 1.2 kg/day
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=156 The Fibrin Pad CV Phase III Study
Cardiovascular Disease
Primary: Number of Participants With Hemostasis at the Target Bleeding Site (TBS) at 3 Minutes Following Treatment Application. — 57; 36 Participants — p=0.0001
Phase 2 N=421 Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma
Asthma
Primary: Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) — 0.0260; 0.0320; 0.0385; 0.0444 Litres (L)
Phase 3 N=812 Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)
Bladder Cancer
Primary: Recurrence Rate at 2 Years — 112; 138; 170; 160 Participants — p=0.1094
Phase 3 N=17 Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD
COPD
Primary: Exertional Dyspnea Intensity at Isotime Exercise. — 3.9; 3.4 units on a scale — p=0.090
Phase 2 N=72 Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma
Glioblastoma
Primary: Safety, Tolerability, and Feasibility of Combination Intra-operative 5-ALA and Gliadel Wafers Prior to Adjuvant Radiotherapy Plus Temozolomide — 62; 9; 6; 45 Participants
N/A N=53 Effect of Macrolide Antibiotics on Airway Inflammation in People With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Levels of PGP From Sputum Samples of COPD Patients Being Treated With Azithromycin. — 2.27; 5.15 ng/mL — p=0.045
N/A N=30 The Various Effects of Gaseous Albuterol on Serum Lactate
Asthma
Primary: Number of Subjects With a Change From Baseline Serum Lactate Following a One Hour Albuterol Nebulizer Treatment. — -0.15; 0.77 mmol/L
N/A N=64 Attention Bias Modification Training for Child Anxiety CBT Nonresponders
Anxiety Disorders
Primary: Clinician Rating on the Pediatric Anxiety Rating Scale — 8.88; 8.12 units on a scale
N/A N=1,701 SJ4 Post Approval Study in Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Defibrillator Patients
Tachyarrhythmias · Sudden Cardiac Death · Heart Failure
Primary: Right Ventricle (RV) Bipolar Capture Thresholds — 0.92 Volts
N/A N=17 Musculotendinous Tissue Repair Unit and Reinforcement (MTURR)
Traumatic Injury · Muscle Injury · Tendon Injury
Primary: Percent Change From Baseline in the Rectified and Integrated EMG Signal of the Tibialis Anterior Muscle At 24 Weeks Post-Operative — 1333 % change
N/A N=121 Developmental Regulation of Proteins Responsible for Transforming Drugs in the Body
Healthy
Primary: Change in CYP2D6 Drug Metabolism Phenotype With Age — -1.974; -2.083; -2.162; -2.073 unitless ratio — p=0.035
Phase 3 N=60 Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
Autism
Primary: ADHD Rating Scale (ADHDRS)-Home Version Total Score (Randomized Phase) — 28.7; 34.0 units on a scale
Phase 3 N=169 Calcium Hydroxide, Mineral Trioxide Aggregate and Biodentine (Trademark) as Direct Pulp Capping of Permanent Teeth
Caries · Dental Pulp Exposure
Primary: Parameters Evaluated After Treatment — 19; 19; 25; 3 Participants
N/A N=25 Diet and Systemic Inflammation
Low-grade Chronic Inflammation · Intestinal Permeability · Type 2 Diabetes Mellitus
Primary: Fasting Plasma C-reactive Protein — 0.91; 1.07; 1.67; 1.09 mg/L — p=0.403